Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions revolve around the ineffective outcomes of apixaban compared to aspirin in preventing recurrent strokes, often using phrases like 'did not significantly reduce' and referencing the trial's premature cessation. Comments such as 'one of the very exciting stories' suggest a level of interest in the broader implications of the research, while others lament the findings, indicating a spectrum of reactions to the study's conclusions.
There is a mix of support and skepticism regarding the study's conclusions, indicating a neutral stance overall.
Most posts show moderate interest, with some users expressing curiosity about the implications of the findings.
While some discussions delve into the methods and outcomes, others remain surface-level, suggesting a range of engagement.
The perceived impact of the study is seen as mild, with many users acknowledging it but not viewing it as groundbreaking.
Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in both arms. No increased sICH with apixaban. What is the future of ESUS therapy? @hoomankamel https://t.co/uZE8Gy9CYe
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from ARCADIA. @hoomankamel https://t.co/2C7QNv2J8P
Kriptojenik iskemik inme geçirenlerde sol atriyum dilate/fonksiyonları bozuk, saptayamadık ama paroksismal AF gelişiyordur kesin, o yüzden OAK verelim diye düşünüyorsanız
In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin https://t.co/nE3qWf38g3 @JAMA_current
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/FMzaEgVhGC
Prof. Dr. Christoph Kleinschnitz from Essen explains current therapeutic strategies for patients with acute stroke. This discussion, held on July 14, 2025, includes insights on the impact of atrial cardiopathy on stroke…
Professors Tobias Geisler and Hooman Kamel discuss their respective ATTICUS and ARCADIA trials, focusing on antithrombotic treatment for patients with Embolic Stroke of Undetermined Source (ESUS). Their studies compare…
Join our scientific team as we discuss the top clinical papers of February 2024, including the ARCADIA trial that evaluated apixaban for stroke prevention in patients with atrial cardiopathy. Discover insights from…
Image credits: 1. DOI 10.3389/fneur.2022.952462 2,3. DOI 10.1161/STROKEAHA.116.016414 4. DOI 10.1111/ene.12673 5,6. DOI 10.1001/jama.2023.27188 7. DOI 10.4070/kcj.2022.0258
RT @tenridayo123: 一方でatrial cardiopathyのcryptogenic strokeに対するDOACの再発予防のRCTではアスピリンと比べて再発は減りませんでした。atrial cardiopathyの定義をどうするかはまだ議論の残るところかなと…
一方でatrial cardiopathyのcryptogenic strokeに対するDOACの再発予防のRCTではアスピリンと比べて再発は減りませんでした。atrial cardiopathyの定義をどうするかはまだ議論の残るところかなと思っています。 https://t.co/wlG5YENsvN
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/SLnIdM4OZv
RT @StrokeAHA_ASA: Article Commentary: “Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy” In th…
Article Commentary: “Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy” In this #BloggingStroke post, Sucharita Ray discusses @JAMA_current article by @hoomankamel et al. @ChaturvediNeuro @dkleindo @MitchElkind https://t.co/FWJeSfR5wC
RT @PBasiukiewicz: @InPartibusInfid Była taka koncepcja, żeby leczyć przeciwzakrsepowo atriopatię u osób z ESUS. https://t.co/hOvT0VidiP…
@InPartibusInfid Była taka koncepcja, żeby leczyć przeciwzakrsepowo atriopatię u osób z ESUS. https://t.co/hOvT0VidiP Była też koncepcja żeby leczyć subkliniczne AF. https://t.co/Gk5B2OX5ah OBIE upadły.
RT @cpgale3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/FMzaEgVhGC
RT @JAMA_current: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
RT @cpgale3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/FMzaEgVhGC
RT @cpgale3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/FMzaEgVhGC
RT @JAMANetwork: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinic…
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/FMzaEgVhGC
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical, from @JAMA_current, free to read online during #AANAM https://t.co/7oFFUbj43D https://t.co/PX5ayIxYHl
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical, from JAMA, free to read online during #AANAM https://t.co/v9tqwY0wBl https://t.co/9g2QUF6Otk
New today: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/SpDV5UV3v1 #CME
New from JN Learning: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/myXOC8vS0G
Our next journal club meeting! Date: Thursday, March 7th at 4.00 pm Dr. Simon Christie will present the ARCADIA phase 3 trial on "Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy" https://t.co/CQozBvTkRJ
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/K2EsLx1yM7
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @flora_peyvandi: In patients with cryptogenic #stroke and evidence of atrial cardiopathy without atrial fibrillation, #apixaban did not…
In patients with cryptogenic #stroke and evidence of atrial cardiopathy without atrial fibrillation, #apixaban did not significantly reduce recurrent stroke risk compared with #aspirin. https://t.co/m95PVVXQaq
Now trending on the AMA Ed Hub: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/VBE33G3ugf #CME
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @JAMA_current: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sign…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @JAMA_current: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sign…
RT @CanbolatIP: Kriptojenik iskemik inme geçirenlerde sol atriyum dilate/fonksiyonları bozuk, saptayamadık ama paroksismal AF gelişiyordur…
RT @JAMA_current: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sign…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
Kriptojenik iskemik inme geçirenlerde sol atriyum dilate/fonksiyonları bozuk, saptayamadık ama paroksismal AF gelişiyordur kesin, o yüzden OAK verelim diye düşünüyorsanız
In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. https://t.co/Mx7qrcYdkp https://t.co/EWow0NSY5c
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
RT @NAsdaghi: Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in bo…
Apixaban is not superior to ASA in prevention of recurrent stroke in ESUS+ atrial cardiopathy. 4% annual rate of stroke in both arms. No increased sICH with apixaban. What is the future of ESUS therapy? @hoomankamel https://t.co/uZE8Gy9CYe
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @bryanacotton1: #StickWithAspirin Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCAD…
RT @gbiondizoccai: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sig…
RT @gbiondizoccai: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sig…
RT @gbiondizoccai: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sig…
https://t.co/HnkSaPyKd2 https://t.co/opt5iAWpew https://t.co/kbM6S7zXTJ https://t.co/BEOQLgmLZs https://t.co/O1trixzvIQ https://t.co/NWXP5nktZP https://t.co/zh4Znr4OJJ https://t.co/SGrgMrCJpm https://t.co/ZICidUT7hw
Fibrin is a fibrous, non-globular protein involved in the clotting of blood., JAMA Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy, anticoagulation and antiplatelet therapy,
RT @gbiondizoccai: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sig…
RT @gbiondizoccai: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sig…
RT @gbiondizoccai: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not sig…
In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin https://t.co/nE3qWf38g3 @JAMA_current
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
"In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin" Me queda la duda de la eficacia en este contexto de la antiagregación https://t.co/4vzJuo82qA
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
RT @sheth_kevin: One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from…
One of the very exciting stories in secondary prevention of stroke in recent years. Excited to see what more we learn from ARCADIA. @hoomankamel https://t.co/2C7QNv2J8P
RT @bryanacotton1: #StickWithAspirin Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCAD…
#StickWithAspirin Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial | Cardiology | JAMA | JAMA Network https://t.co/aMHHKzX9L3
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/yGGrCjinjn
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/okbSqW54mM
Trending on PubMed: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. https://t.co/N8ZXGga8Hr
RT @CulebrasCruz: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/5eH29GUWn0
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/5eH29GUWn0
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/52fhmKNYup
RT @KBibbinsDomingo: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA RCT @hoomank…
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy - The ARCADIA Randomized Clinical Trial
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy @JAMANetwork #stroke #DOAC https://t.co/yKFrd7ht4H
原因不明の脳卒中を患い、心房細動のない心房性心疾患の証拠がある患者において、アピキサバンはアスピリンと比較して脳卒中再発リスクを有意に低下させることはなかった。 https://t.co/luNDl7ds2Z
RT @CeoImed: ｢原因不明の脳卒中に対する再発予防｣ JAMA ･ 原因不明の虚血性脳卒中に対する再発予防としての、アスピリンとApixaban（抗凝固薬）のRCT study ･ 約1000人を対象 ･ 脳卒中再発率はともに年4.4%で有意差なし ･ 結論: ど…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @CeoImed: ｢原因不明の脳卒中に対する再発予防｣ JAMA ･ 原因不明の虚血性脳卒中に対する再発予防としての、アスピリンとApixaban（抗凝固薬）のRCT study ･ 約1000人を対象 ･ 脳卒中再発率はともに年4.4%で有意差なし ･ 結論: ど…
RT @CeoImed: ｢原因不明の脳卒中に対する再発予防｣ JAMA ･ 原因不明の虚血性脳卒中に対する再発予防としての、アスピリンとApixaban（抗凝固薬）のRCT study ･ 約1000人を対象 ･ 脳卒中再発率はともに年4.4%で有意差なし ･ 結論: ど…
｢原因不明の脳卒中に対する再発予防｣ JAMA ･ 原因不明の虚血性脳卒中に対する再発予防としての、アスピリンとApixaban（抗凝固薬）のRCT study ･ 約1000人を対象 ･ 脳卒中再発率はともに年4.4%で有意差なし ･ 結論: どちらの薬剤でも再発効果は同等 https://t.co/d2g4t34QIr
@JudithterSchure @peder_isager @annemscheel @lakens Finally....this paper is interesting on the whole SESOI issue. https://t.co/ovNyRTyKrB They seem to have powered the study based on assuming a meaningful effect (but not really used that meaningful effect otherwise in the design choices).
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @FormigaFrancesc: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/ePyDwu7Wm0
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke in patients with cryptogenic stroke and evidence of atrial cardiopathy? https://t.co/BSirg7vUE8 https://t.co/UfsuPijdQj
RT @KBibbinsDomingo: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA RCT @hoomank…
RT @KBibbinsDomingo: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA RCT @hoomank…
RT @KBibbinsDomingo: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA RCT @hoomank…
RT @SantasEnrique: Apixaban vs aspirina en pacientes con ictus
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA RCT @hoomankamel @WeillCornell @WCMCNeurology & colleagues https://t.co/TOjPPhgJEJ …our Top Viewed this week at JAMA https://t.co/Ae3RctlVM6
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA RCT @hoomankamel @WeillCornell @WCMCNeurology & colleagues jamanetwork.com/journals/jam... …our Top Viewed this week at JAMA #medsky
RT @FormigaFrancesc: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/ePyDwu7Wm0
RT @FormigaFrancesc: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/ePyDwu7Wm0
RT @FormigaFrancesc: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/ePyDwu7Wm0
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/evyBI4NnhS
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @JAMA_current: Top viewed @JAMA_Current article: Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke…
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @VishankShah3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @air_garcia: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/k2i04VAJ5X
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #science #publication #research #publications https://t.co/UqAgLI9CP1
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @air_garcia: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/k2i04VAJ5X
RT @drbennisahmed: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy The ARCADIA Randomized Clini…
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy The ARCADIA Randomized Clinical Trial cryptogenic stroke and evidence atrial cardiopathy without AF apixaban did not significantly reduce recurrent stroke risk https://t.co/GOgddIbZ57 https://t.co/OPMkMEgmmM
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @VishankShah3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/cPve8IK8Nj
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @beckerbarroso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/l1ly5oYJOS
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @VishankShah3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @air_garcia: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/k2i04VAJ5X
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/k2i04VAJ5X
RT @FormigaFrancesc: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/ePyDwu7Wm0
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @VishankShah3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
RT @GendronNico: ❌Apixaban to prevent recurrence after Cryptogenic Stroke in Patients with Atrial Cardiopathy ❤️
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @beckerbarroso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/l1ly5oYJOS
❌Apixaban to prevent recurrence after Cryptogenic Stroke in Patients with Atrial Cardiopathy ❤️
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @ValleAlfonso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy #ARCADIA Trial
RT @AbelNovoa: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy. Los ECAs negativos son una rara…
RT @VishankShah3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
RT @VishankShah3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/ePyDwu7Wm0
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy. Los ECAs negativos son una rara joya en las publicaciones de primer nivel y ponen de manifiesto la complejidad causal https://t.co/YvfEG9cxpD
RT @VishankShah3: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clini…
RT @mel_para: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/BT8ZvoikB2
RT @beckerbarroso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/l1ly5oYJOS
RT @beckerbarroso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/l1ly5oYJOS
RT @beckerbarroso: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/l1ly5oYJOS
RT @Jentan7477: Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/eCFylYFsVi
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/eCFylYFsVi
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy https://t.co/BT8ZvoikB2